

Lupin signs agreement with Biomm in Brazil

03 December 2021 | News

The distribution and marketing agreement for Pegfilgrastim in Brazil



Lupin has entered into an exclusive distribution and marketing agreement with Biomm in Brazil. Under the terms of the agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.

Lupin had earlier received the US FDA acceptance of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim) through a filing using the 351(k) pathway.

Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.